ERIPIRA-C PLUS – Citicoline 500mg + Piracetam 800mg Tablets
Citicoline and Piracetam are both used in cognitive and post-stroke recovery, but they act at different levels of the same problem. Citicoline supplies precursors for rebuilding neuronal membranes; Piracetam alters the fluidity and function of membranes already present. Combining them addresses structural repair and functional signalling together rather than duplicating a single pathway.
Product Specifications
Brand Name: ERIPIRA-C PLUS
Composition: Citicoline 500mg + Piracetam 800mg
Dosage Form: Tablet
Packing Type: Alu-Alu
Packing: 10x1x10
Therapeutic Category: Neuropsychiatry, CNS, Neuroprotectives
Manufacturing: WHO-GMP certified facility
Prescription Status: Schedule H
Storage: Store below 25°C, protect from light and moisture
Composition
Citicoline — 500 mg — Precursor for phosphatidylcholine synthesis; supports neuronal membrane formation and repair
Piracetam — 800 mg — Nootropic agent; influences neuronal membrane fluidity and cholinergic neurotransmission
Mechanism of Action
Citicoline is an intermediate in the synthesis of phosphatidylcholine, one of the principal structural phospholipids of neuronal membranes. Following ischemic injury, progressive membrane breakdown contributes to ongoing neuronal loss, and supplying substrate for membrane reconstruction is the rationale for its use in stroke recovery. Citicoline also feeds into acetylcholine synthesis, relevant to memory and cognitive function.
Piracetam acts on a separate level. Rather than supplying structural material, it modifies the behaviour of existing membranes, improving fluidity and thereby influencing receptor and neurotransmitter function across the membrane surface. It has additionally been associated with effects on erythrocyte deformability and cerebral microcirculation, relevant where perfusion is compromised. The two components therefore complement rather than overlap.
Presentation
Supplied in 10x1x10 Alu-Alu packing. Alu-Alu blistering provides a complete moisture and light barrier on both faces of the blister, in contrast to the single-sided protection of standard PVC blisters, which is relevant to stability across the humidity ranges encountered in much of India.
Clinical Applications
- Post-stroke cognitive and neurological recovery
- Cognitive impairment associated with cerebrovascular insufficiency
- Traumatic brain injury and post-head-injury recovery
- Age-related memory and cognitive decline, on physician assessment
- Vertigo of central origin
Prescriber Profile
Neurologists form the primary prescribing base, particularly in post-stroke and post-head-injury protocols. Neurosurgeons prescribe it in post-operative neurological recovery. Physicians and geriatricians account for use in cognitive decline associated with reduced cerebral perfusion, and psychiatrists encounter it in patients with cognitive symptoms alongside other neuropsychiatric management.
Dosage and Administration
As prescribed by a Registered Medical Practitioner. This is a Schedule H drug — sale by retail is permitted only against the prescription of a Registered Medical Practitioner.
Safety Information
Dose adjustment may be required in renal impairment, as Piracetam undergoes renal clearance. Treatment should not be discontinued abruptly in patients on long-term therapy without physician guidance. Not indicated in known hypersensitivity to either component. Store below 25°C, protect from light and moisture. Keep out of reach of children.
Range Positioning
ERIPIRA-C PLUS sits within the core neuropsychiatry and CNS range at Eridanus Healthcare, alongside the antiepileptic, antidepressant and neuropathy segments. A combination covering both membrane repair and membrane function gives a clearer basis for prescriber discussion than single-molecule alternatives already established in the segment.
PCD Pharma Franchise Availability
ERIPIRA-C PLUS is available for PCD Pharma Franchise across India. Territory rights are allotted on a monopoly basis subject to availability, and franchise partners receive promotional inputs and product literature across the neuropsychiatry and CNS range.
Frequently Asked Questions
Why combine Citicoline with Piracetam rather than using either alone?
Citicoline supplies precursors for rebuilding neuronal membranes, while Piracetam acts on the fluidity and function of existing membranes. The two operate at different levels of the same process rather than duplicating each other.
What advantage does Alu-Alu packing offer?
Alu-Alu provides a full moisture and light barrier on both faces of the blister, compared with the single-sided protection of standard PVC blistering.
How quickly does response develop?
Cognitive and neurological recovery is gradual, and response is assessed over weeks by the treating physician rather than over a few days.
Does ERIPIRA-C PLUS require dose adjustment in any patient group?
Dose adjustment may be required in renal impairment, since Piracetam is cleared renally. This is determined by the prescribing physician.
Is ERIPIRA-C PLUS available for PCD Pharma Franchise in India?
Yes. ERIPIRA-C PLUS is available for PCD Pharma Franchise across India under Eridanus Healthcare, with monopoly-basis territory rights subject to availability.
Which prescribers form the target base for Citicoline and Piracetam tablets in a PCD Pharma Franchise range?
Neurologists and neurosurgeons are the primary prescribers, with physicians, geriatricians and psychiatrists as secondary coverage — relevant for franchise partners building a neuropsychiatry and CNS portfolio.
How can a distributor apply for PCD Pharma Franchise rights for ERIPIRA-C PLUS?
Distributors and pharmaceutical professionals holding a valid Drug Licence and GST registration may contact Eridanus Healthcare to discuss territory availability and franchise terms.
Related Products
This page is intended for pharmaceutical distributors, wholesalers, and healthcare professionals. Product information is provided for commercial and educational reference and is not a substitute for professional medical advice. Eridanus Healthcare does not sell directly to patients. This is a Schedule H drug — to be sold by retail only on the prescription of a Registered Medical Practitioner. All trade enquiries are subject to valid Drug Licence and GST verification.